Hims & Hers Rises on Legal Clearance, Target Raised to $29; Progyny Downgraded Amid 2026 Earnings Caution

Barclays has upgraded Hims & Hers (HIMS) to a $29 price target following the resolution of legal challenges surrounding its previously announced acquisition by Novo Nordisk. The clearance of the regulatory overhang removes a significant uncertainty that had weighed on the stock, reinforcing confidence in the company's strategic execution and digital health momentum. The move reflects growing optimism in the consumer healthcare sector, particularly for companies with scalable telemedicine platforms and direct-to-consumer models. Progyny (PGNY), a fertility technology firm, faces a different trajectory as Canaccord downgrades the stock due to cautious near-term earnings projections. The firm cites elevated operational costs and uncertain revenue timing, projecting limited profitability through 2026 despite long-term market tailwinds in reproductive health. This downgrade suggests investors should temper expectations for near-term earnings growth, even as the underlying market opportunity remains intact. The divergence in analyst sentiment underscores the importance of execution risk and regulatory clarity in the digital wellness space. HIMS' stock has gained 14% in the past month, outperforming the broader healthcare sector, while PGNY has underperformed by 8% over the same period. These movements reflect investor focus on deal certainty, scalability, and the ability to convert digital engagement into sustainable revenue. Market participants are closely monitoring how these companies navigate post-deal integration and cost discipline. The HIMS-Novo synergy potential and PGNY’s upcoming clinical and commercial milestones will likely influence stock direction in the coming quarters.